Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3070 | Prednisone tablet Wiki | 1.00 |
| drug4749 | standard of care Wiki | 0.58 |
| drug963 | Colchicine Wiki | 0.29 |
Navigate: Correlations HPO
There is one clinical trial.
Hospital health workers involved in the coronavirus epidemic are facing several challenges such as direct exposure and involvement in the resolution of major public health emergencies, exposure to potentially fatal contamination, physical exhaustion , unadjusted work organizations, the unusual number of deaths among patients, colleagues and close relatives, and significant ethical challenges in decision-making. Preliminary data suggests that frontline and lay professionals suffer from different types of psychological distress. These data highlight the importance of screening for psychological distress in response to the scale of the pandemic and the provision of targeted psychological interventions, such as Eye Movement Desensitization and Reprocessing (EMDR, desensitization and neuro-emotional integration by eye movements), to improve the psychological well-being of healthcare workers exposed to COVID-19. This project is both a cohort study with the proposal of a randomized trial to evaluate an intervention adapted to the exceptional circumstances of the crisis. As such, it is designed as Trial(s) Within Cohort design (TWIC).
Description: This study is investigating three different conditions (PTSD, Depression and Burnout) each assessed with its own primary endpoint. Thus, the trial will have three primary endpoints. Change over a 6 months period in symptoms of PTSD measured by the Post-Traumatic Stress Disorder Checklist Scale for Diagnostic and Statistical Manual of mental disorders fifth edition ((DSM-5), PCL-5). The PCL-5 score is on a scale from 0 to 80. The higher the score, the higher the level of PTSD symptoms are.
Measure: Efficacy on symptoms of Post-Traumatic Stress Disorder Time: From inclusion to 6 months after inclusionDescription: Change over a 6 months period in symptoms of Burnout measured by the Professional Quality Of Life questionnaire (ProQOL). The ProQOL score is on a scale from 30 to 150. The higher the score, the higher the level of Burnout symptoms are.
Measure: Efficacy on symptoms of Burnout Time: From inclusion to 6 months after inclusionDescription: Change over a 6 months period in symptoms of depression measured by the Patient Health Questionnaire (PHQ-9). The PHQ-9 score is on a scale from 0 to 27. The higher the score, the higher the level of depression symptoms are.
Measure: Efficacy on symptoms of Depression Time: From inclusion to 6 months after inclusionDescription: Change over a 3 months period in symptoms of PTSD measured by the Post-Traumatic Stress Disorder Checklist Scale for Diagnostic and Statistical Manual of mental disorders fifth edition ((DSM-5), PCL-5). The PCL-5 score is on a scale from 0 to 80. The higher the score, the higher the level of PTSD symptoms are.
Measure: Short-term efficacy on symptoms of PTSD Time: From inclusion to 3 months after inclusionDescription: Change over a 3 months period in symptoms of Burnout measured by the Professional Quality Of Life questionnaire (ProQOL). The ProQOL score is on a scale from 30 to 150. The higher the score, the higher the level of Burnout symptoms are.
Measure: Short-term efficacy on symptoms of Burnout Time: From inclusion to 3 months after inclusionDescription: Change over a 3 months period in symptoms of depression measured by the Patient Health Questionnaire (PHQ-9). The PHQ-9 score is on a scale from 0 to 27. The higher the score, the higher the level of depression symptoms are.
Measure: Short-term efficacy on symptoms of Depression Time: From inclusion to 3 months after inclusionDescription: Change over a 12 months period in symptoms of PTSD measured by the Post-Traumatic Stress Disorder Checklist Scale for Diagnostic and Statistical Manual of mental disorders fifth edition ((DSM-5), PCL-5) for the participants who will be enrolled in the trial at M0 of the cohort. The PCL-5 score is on a scale from 0 to 80. The higher the score, the higher the level of PTSD symptoms are.
Measure: Long-term efficacy on symptoms of PTSD Time: From inclusion to 12 months after inclusionDescription: Change over a 12 months period in symptoms of Burnout measured by the Professional Quality Of Life questionnaire (ProQOL) for the participants who will be enrolled in the trial at M0 of the cohort. The ProQOL score is on a scale from 30 to 150. The higher the score, the higher the level of Burnout symptoms are.
Measure: Long-term efficacy on symptoms of Burnout Time: From inclusion to 12 months after inclusionDescription: Change over a 12 months period in symptoms of depression measured by the Patient Health Questionnaire (PHQ-9) for the participants who will be enrolled in the trial at M0 of the cohort. The PHQ-9 score is on a scale from 0 to 27. The higher the score, the higher the level of depression symptoms are.
Measure: Long-term efficacy on symptoms of Depression Time: From inclusion to 12 months after inclusionDescription: Change over a 6 months period in anxiety measured by the Generalized Anxiety Disorder-7 questionnaire (GAD-7). The GAD-7 score is on a scale from 0 to 21. The higher the score, the higher the level of anxiety symptoms are.
Measure: Efficacy on symptoms of Anxiety Time: From inclusion to 6 months after inclusionDescription: Change over a 12 months period in anxiety measured by the Generalized Anxiety Disorder-7 questionnaire (GAD-7) for the participants who will be enrolled in the trial at M0 of the cohort. The GAD-7 score is on a scale from 0 to 21. The higher the score, the higher the level of anxiety symptoms are.
Measure: Long-term efficacy on symptoms of Anxiety Time: From inclusion to 12 months after inclusionDescription: Number of suicide attempts over a 6-month period from baseline
Measure: Efficacy on suicide attempts Time: From inclusion to 6 months after inclusionDescription: Changes in the level of suicidal ideation over a 6 months period from baseline measured by Visual Analog Scale (VAS). The VAS is on a scale from 0 to 10. The higher the VAS score, the higher suicidal ideation level is.
Measure: Efficacy on suicidal ideation Time: From inclusion to 6 months after inclusionDescription: Changes in the level of suicidal ideation over a 12 months period from baseline measured by Visual Analog Scale (VAS) for the participants who are enrolled in the trial at M0 of the cohort. The VAS is on a scale from 0 to 10. The higher the VAS score, the higher suicidal ideation level is.
Measure: Long-term efficacy on suicidal ideation Time: From inclusion to 12 months after inclusionDescription: Change in the impact of health on functioning (Role Emotional (RE) subdomain of the MOS Short Form-36 health survey v1.3 (SF-36)) over a 6 months period from baseline. The RE score is on a scale from 0 to 100. The higher the score, the better Role Emotional is.
Measure: Efficacy on the impact of health on functioning: Role Emotional Time: From inclusion to 6 months after inclusionDescription: Change in the impact of health on functioning (Role Emotional (RE) subdomain of the MOS Short Form-36 health survey v1.3 (SF-36)) over a 12 months period from baseline for the participants who are enrolled in the trial at M0 of the cohort. The RE score is on a scale from 0 to 100. The higher the score, the better Role Emotional is.
Measure: Long-term efficacy on the impact of health on functioning: Role Emotional Time: From inclusion to 12 months after inclusionDescription: Change in the impact of health on functioning (Role Physical (RP) subdomain of the MOS Short Form-36 health survey v1.3 (SF-36)) over a 6 months period from baseline. The RP score is on a scale from 0 to 100. The higher the score, the better Role Physical is.
Measure: Efficacy on the impact of health on functioning: Role Physical Time: From inclusion to 6 months after inclusionDescription: Change in the impact of health on functioning (Role Physical (RP) subdomain of the MOS Short Form-36 health survey v1.3 (SF-36)) over a 12 months period from baseline for the participants who are enrolled in the trial at M0 of the cohort. The RP score is on a scale from 0 to 100. The higher the score, the better Role Physical is.
Measure: Long-term efficacy on the impact of health on functioning: Role Physical Time: From inclusion to 12 months after inclusionDescription: Evolution of substance use over 6 months
Measure: Substance use Time: From inclusion to 6 months after inclusionDescription: Evolution of substance use over 12 months for the participants who are enrolled in the trial at M0 of the cohort
Measure: Long-term substance use Time: From inclusion to 12 months after inclusionDescription: Evolution of medication use over 6 months
Measure: Medication use Time: From inclusion to 6 months after inclusionDescription: Evolution of medication use over 12 months for the participants who are enrolled in the trial at M0 of the cohort
Measure: Long-term medication use Time: From inclusion to 12 months after inclusionDescription: Number of consultations of health professionals within the period of follow-up (general practitioner, psychiatrist, psychotherapist, psychologist, professionals who are practicing alternative medicines); Occurrence of EMDR therapy within the control group; Number of visits at the emergency unit of a hospital; Number of nights spent in hospital as a patient (short-term); Number of nights spent in rehabilitation facilities as a patient.
Measure: Health care utilization Time: From inclusion to 6 months after inclusionDescription: Number of consultations of health professionals within the period of follow-up (general practitioner, psychiatrist, psychotherapist, psychologist, professionals who are practicing alternative medicines); Occurrence of EMDR therapy within the control group; Number of visits at the emergency unit of a hospital; Number of nights spent in hospital as a patient (short-term); Number of nights spent in rehabilitation facilities as a patient. For the participants who are enrolled in the trial at M0 of the cohort
Measure: Long-term health care utilization Time: From inclusion to 12 months after inclusionDescription: Proportion of those who will be offered EMDR and will actually receive EMDR
Measure: Acceptability of EMDR in the EMDR group Time: From inclusion to 12 months after inclusionDescription: Number of sessions attended over the total planned number
Measure: Compliance in the EMDR group Time: From inclusion to 12 months after inclusionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports